Marshall Wace, LLP Aldeyra Therapeutics, Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $755,309 - $1.26 Million	106,232 Added 137.78%	183,337 $1.54 Million
Q1 2023 May 15, 2023	SELL	$5.77 - $9.93 $1.42 Million - $2.44 Million	-245,476 Reduced 76.1%	77,105 $765,000
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $621,883 - $867,943	122,418 Added 61.16%	322,581 $2.25 Million
Q3 2022 Nov 14, 2022	BUY	$3.8 - $7.74 $465,431 - $948,010	122,482 Added 157.67%	200,163 $1.07 Million
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $188,764 - $376,752	77,681 New	77,681 $309,000
Q4 2018 Feb 14, 2019	SELL	$7.26 - $13.29 $114,962 - $210,447	-15,835 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $107,678 - $227,232	15,835 New	15,835 $219,000

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $318M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.